NCT00777946
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone
See it on ClinicalTrials.gov ↗820 people
39.5%
60.5%
324 womenmiddle line = equal numbers496 men
- Phase
- PHASE3
- Paid for by
- Novartis
- Finished
- 2009-05
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 54.6 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant or nursing (lactating) women”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or nursing (lactating) women”
- No women who could get pregnant
Most women roughly 15–50 years old were turned away.
“Women of child-bearing potential”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Previous or current diagnosis of heart failure New York Heart Association (NYHA Class II-IV)”
- No diabetes
Women with diabetes were turned away.
“Uncontrolled Type 1 or Type 2 diabetes mellitus”
Study titles and rules are shown in their original English.